TWiV 1104: Clinical update with Dr. Daniel Griffin

This Week in Virology

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles before addressing results of Pfizer’s phase 3 RSV vaccine clinical trial for adults under 60, RSV, influenza and SARS-CoV-2 circulation, differences between rural and urban communities dealing with SARS-CoV-2 infections, the latest statistics on influenza and COVID-19 circulation, restates the guidelines for spring administration of COVID vaccines boosters, discusses the emergency use application of a pre-exposure prophylactic. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, how long COVID affects the brain and associates with an increase in allergic incidents as well as if post SARS-CoV-2 infected patients are unable to exercise or have functional limitations. For more information about this body of work, listen to TWiV 1088.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Measles tracking (CDC)
• Measles just this year (MMWR)
• ABRYSVO phase 3 results (Pfizer)
• RSV surveillance (CDC)
• Influenza/flu surveillance (CDC)
• Provisional deaths due to COVID-19 (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Rural-urban differences in COVID-19 mortality and hospitalizations (OFID)
• Spring COVID-19 booster recommendations (CIDRAP)
• Older adult spring booster available (CDC)
• Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)
• EUA for pemgarda (FDA)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Nirmatrelvir for vaccinated or unvaccinated COVID-19 patients (NEJM)
• Assessment for clinical usefulness (NEJM)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• Updated respiratory virus guidances (CDC)
• What do when your heathcare provider is infected with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Long COVID evidence based review TWiV shout out (TWiV 1088)
• Brian and cognitive changes in long COVID patients (BRAIN)
• Allergic disease incidents after COVID-19 (Nat Comm)
• Can post COVID patients exercise or do they have functional limitations (JAMA Network Open)
• Contribute to our ASTMH fundraiser at PWB 37:06
• Letters read on TWiV 1102 37:56
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [e-mail]